New study confirms targeted therapy improves pancreatic cancer survival
Researchers found that a new drug improved survival outcomes for patients with advanced pancreatic cancer at a recent medical congress.
Dr. Zev Wainberg presented findings from a phase 3 trial showing patients lived longer on the new treatment than those on standard chemo. The data included groups with various RAS mutations and those without any specific mutation identified in their tumors.
This analysis covered approximately five hundred patients who had already received prior treatments for their metastatic disease. Scientists examined how survival outcomes changed based on the specific RAS mutation type found in each individual tumor sample.
The drug daraxonrasib works by blocking multiple forms of the active RAS protein inside cancer cells effectively. This approach differs from older therapies that targeted only a single genetic mutation within the patient tumor.
Results indicated consistent survival benefits across different chemotherapy comparison groups and previous treatment settings used by patients. The effectiveness held true regardless of the specific chemotherapy regimen selected for the control group comparisons.
“In this analysis, we demonstrate that depending on the individual mutation, daraxonrasib may have a different response”